预约演示
更新于：2025-10-04
Guanfacine hydrochloride
盐酸胍法辛
更新于：2025-10-04
概要
基本信息
简介胍法辛（商品名为Tenex、Intuniv、Estulic）是一种作用于中枢的降压剂和α2肾上腺素受体激动剂。其作用机制是刺激脑内的α2肾上腺素受体，导致交感神经系统活动降低，从而降低血压。此外，胍法辛已被发现对调节注意力和行为的前额叶皮层产生影响，因此对治疗注意力缺陷多动障碍（ADHD）有用。胍法辛最初于1986年被FDA批准用于治疗高血压，授权公司是Promius Pharma LLC。随后在2009年，Takeda制药公司获得了美国批准，用于治疗儿童和青少年的ADHD。目前，它在世界多个国家获得了批准。 |
药物类型 小分子化药 |
别名 Connexyn、guanfacine、Guanfacine hydrochloride (JAN/USP) + [10] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1986-10-27), |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C9H10Cl3N3O |
InChIKeyDGFYECXYGUIODH-UHFFFAOYSA-N |
CAS号29110-48-3 |
关联
87
项与 盐酸胍法辛 相关的临床试验NCT06408246
ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial
NCT06629259
Guanfacine for Alcohol Use Disorder (AUD): a Telehealth Approach
NCT06642181
Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder
100 项与 盐酸胍法辛 相关的临床结果
登录后查看更多信息
100 项与 盐酸胍法辛 相关的转化医学
登录后查看更多信息
100 项与 盐酸胍法辛 相关的专利（医药）
登录后查看更多信息
1,399
项与 盐酸胍法辛 相关的文献（医药）2025-08-31Clinical Psychopharmacology and Neuroscience
Efficacy of Guanfacine for Self-injurious and Aggressive Behaviors through the Reduction of Impulsivity in Borderline Personality Disorder: Two Case Reports and a Literature Review
Article
作者: Ueno, Shu-ichi ; Ochi, Shinichiro ; Hashida, Hidetoshi ; Iga, Jun-ichi ; Mori, Hiroaki
Borderline personality disorder (BPD) is a complex psychiatric disorder characterized by emotional instability, impulsivity, and self-destructive behavior. In BPD, impulsivity is particularly concerning because it can lead to suicidal behavior, self-injury, and aggressive behavior. Guanfacine, an α2A-adrenergic receptor agonist, is approved for attention deficit hyperactivity disorder (ADHD) to reduce its symptoms. This report presents two cases of BPD, one with and one without comorbid ADHD, demonstrating significant improvement in impulsivity-related symptoms, including self-injury and aggression, following treatment with guanfacine. Case 1, a 29-year-old woman with comorbid ADHD, experienced worsening symptoms after discontinuation of guanfacine. Restarting guanfacine at 2 mg/day and increasing the dose to 6 mg/day resulted in significant improvements in self-injury, aggression, and impulsivity. Case 2, a 24-year-old woman without ADHD, showed severe impulsivity and had to be temporarily isolated in hospitalization because of self-injury and aggressive behavior; she showed similar benefits after starting guanfacine at 2 mg/day and increasing it to 4 mg/day, reducing her symptoms. A literature review highlighted the potential role of guanfacine in the treatment of impulsivity, self-injury, and aggressive behavior in neuropsychiatric disorders. Guanfacine is thought to improve prefrontal cortex (PFC) dysfunction. Since PFC dysfunction is thought to play a role in the etiology of BPD, the ability of guanfacine to alleviate PFC dysfunction may explain its efficacy in BPD. These findings suggest that guanfacine may be a promising pharmacological option for the treatment of impulsivity in BPD.
2025-06-15Cureus Journal of Medical Science
Guanfacine for Treatment of Anxiety and Panic-Induced Vasovagal Syncope in the Intensive Care Unit
Article
作者: Nolasco, Diego ; Jiang, Shixie ; Gunther, Matthew ; Janssen, Brandon ; Czuma, Richard
This case report describes the successful use of oral guanfacine, a centrally acting alpha-2 agonist, for treating panic-induced vasovagal syncope in a 68-year-old intensive care unit (ICU) patient recovering from lung transplant and cardiac complications. The patient experienced recurrent episodes of severe anxiety and syncope triggered by physical therapy, unresponsive to standard anxiolytics. Guanfacine was chosen given its less pronounced cardiovascular effects and modulation of norepinephrine, and titrated over 10 days, leading to complete resolution of symptoms without adverse effects or recurrence. The patient resumed rehabilitation and guanfacine was successfully tapered prior to discharge. This case highlights guanfacine as a potentially useful anxiolytic option for ICU patients even with cardiovascular vulnerability as it exhibits less pronounced cardiovascular effects and may therefore be considered safer than other alpha-2 agonists.
2025-06-13EXPERT OPINION ON PHARMACOTHERAPY
Pharmacological management for insomnia in children and adolescents with autism and attention deficit and hyperactivity disorder
Review
作者: Randazzo, Ludovico ; Mammarella, Valeria ; Romano, Sara ; Bruni, Oliviero ; Breda, Maria
INTRODUCTION:
Insomnia is common in children and adolescents with autism spectrum disorder (ASD) and/or attention deficit and hyperactivity disorder (ADHD), with significant implications for quality of life and prognosis. Although non-pharmacological interventions represent the first-line approach, they are not always effective. Therefore, it is important to determine when a pharmacological treatment can be indicated and which compound to prefer based on evidence of efficacy and safety.
AREAS COVERED:
The literature evidence related to the pharmacological treatment of insomnia in ASD and/or ADHD is discussed. We present data on drugs and supplements used and considerations about the choice of starting a pharmacological therapy, suggesting clinical advice that may guide clinicians.
EXPERT OPINION:
Untreated insomnia can worsen ASD and ADHD symptoms, impair cognitive function, and reduce quality of life. Targeted interventions are essential. Behavioral strategies, with or without melatonin, are recommended after evaluating comorbidities and medications. Off-label treatments for children with ASD include antihistamines, alpha-adrenergics, trazodone, antidepressants, antipsychotics, anticonvulsants, and hypnotics. For ADHD, options include iron supplementation for restlessness and low ferritin levels, and alpha2-adrenergics like guanfacine and clonidine for their sedative effects.
100 项与 盐酸胍法辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 注意缺陷障碍伴多动 | 美国 | 2009-09-02 | |
| 高血压 | 美国 | 1986-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 46 | Placebo (Placebo) | 鹽選鹹築艱積壓齋淵構(構網艱選廠齋選齋艱簾) = 繭餘簾淵顧築繭繭觸廠 簾夢艱構壓觸遞願襯醖 (鹽壓夢簾醖糧壓餘築觸, 選鹽壓選網鑰蓋廠餘淵 ~ 範艱衊鏇夢鏇蓋築廠願) 更多 | - | 2025-05-06 | ||
(IV Guanfacine) | 鹽選鹹築艱積壓齋淵構(構網艱選廠齋選齋艱簾) = 艱膚憲觸築夢網淵鏇鹽 簾夢艱構壓觸遞願襯醖 (鹽壓夢簾醖糧壓餘築觸, 鑰繭廠築繭築餘憲遞糧 ~ 簾範窪範膚醖壓壓蓋廠) 更多 | ||||||
临床4期 | 28 | 壓醖衊廠廠選鏇鬱夢願(網憲壓壓選鏇淵淵範蓋) = 鏇餘窪積鹽衊艱繭鬱餘 觸鹽壓製齋遞艱鬱顧夢 (窪壓築築願獵築醖鑰夢, 0.617) 更多 | - | 2025-03-20 | |||
临床2期 | 37 | (Lidocaine Alone) | 範壓觸鹽壓製鬱繭襯艱(醖築夢鹽積衊衊獵選範) = 餘顧艱網壓繭憲壓選憲 餘廠願願醖糧襯淵獵糧 (壓繭鏇積觸壓繭夢淵範, 窪齋糧蓋網齋觸範艱簾 ~ 積壓憲繭獵積膚淵觸窪) 更多 | - | 2024-10-17 | ||
(Lidocaine + Guanfacine) | 範壓觸鹽壓製鬱繭襯艱(醖築夢鹽積衊衊獵選範) = 築夢繭齋壓齋廠襯鬱範 餘廠願願醖糧襯淵獵糧 (壓繭鏇積觸壓繭夢淵範, 製蓋鏇憲淵網鑰觸鏇鏇 ~ 繭膚鑰範獵壓繭範淵網) 更多 | ||||||
临床3期 | 100 | Placebo (Placebo) | 鬱築鏇鏇繭築餘獵糧醖(願簾選遞繭網簾簾餘網) = 廠顧顧醖窪衊繭醖鬱範 夢範醖顧淵糧繭顧簾觸 (鏇醖鬱築膚鬱餘衊衊蓋, 3.14) 更多 | - | 2024-04-17 | ||
(Guanfacine) | 鬱築鏇鏇繭築餘獵糧醖(願簾選遞繭網簾簾餘網) = 鏇襯艱簾廠糧鑰鏇鹹構 夢範醖顧淵糧繭顧簾觸 (鏇醖鬱築膚鬱餘衊衊蓋, 3.70) 更多 | ||||||
临床2期 | 74 | Behavioral Counseling+Guanfacine (Study Medication) | 夢選憲築淵遞製膚憲繭(糧鏇遞壓艱構蓋築鏇繭) = 衊鏇積積築淵網糧鬱齋 獵積構顧襯淵鹽糧鏇網 (夢範選簾蓋鬱壓衊鑰齋, 1) 更多 | - | 2024-01-08 | ||
Behavioral Counseling+Guanfacine (Placebo) | 夢選憲築淵遞製膚憲繭(糧鏇遞壓艱構蓋築鏇繭) = 窪範鏇範積遞艱鹽鏇鏇 獵積構顧襯淵鹽糧鏇網 (夢範選簾蓋鬱壓衊鑰齋, 0.96) 更多 | ||||||
临床2期 | 100 | (Guanfacine) | 選繭築繭蓋構壓積淵壓(願鏇蓋膚憲製醖築選襯) = 簾艱網鬱鑰願鹹積築顧 憲網鏇窪廠網觸淵壓膚 (願願壓窪齋衊襯齋遞膚, 5.30) 更多 | - | 2022-08-01 | ||
placebo (Placebo) | 選繭築繭蓋構壓積淵壓(願鏇蓋膚憲製醖築選襯) = 選觸願顧鏇糧網襯構憲 憲網鏇窪廠網觸淵壓膚 (願願壓窪齋衊襯齋遞膚, 5.44) 更多 | ||||||
临床2期 | 121 | (Guanfacine 6mg/Day ER) | 製鹽膚餘鏇獵網廠醖網 = 鹽簾繭淵製鏇鏇糧膚顧 鬱顧窪願鏇壓艱窪壓願 (襯窪膚鹹築簾願簾壓積, 簾構夢糧膚夢鬱觸鹹艱 ~ 製繭鹹獵構憲積鑰觸淵) 更多 | - | 2021-12-29 | ||
Placebo (Placebo) | 製鹽膚餘鏇獵網廠醖網 = 築簾鏇鏇夢憲繭鏇糧願 鬱顧窪願鏇壓艱窪壓願 (襯窪膚鹹築簾願簾壓積, 淵顧鹹餘壓壓選選襯鏇 ~ 製壓網鹹願壓繭範齋齋) 更多 | ||||||
临床2期 | - | 70 | (Guanfacine 3mg/Day) | 襯衊獵選積衊窪窪齋鬱(網獵繭憲憲夢窪鬱簾糧) = 構積衊襯齋艱醖鹹製構 蓋積衊淵獵積願網鏇製 (範積窪蓋衊廠積築衊鏇, 5.217) 更多 | - | 2021-04-21 | |
(Guanfacine 1.5mg/Day) | 襯衊獵選積衊窪窪齋鬱(網獵繭憲憲夢窪鬱簾糧) = 願築餘鏇鬱選選壓鹹廠 蓋積衊淵獵積願網鏇製 (範積窪蓋衊廠積築衊鏇, 5.567) 更多 | ||||||
临床4期 | 41 | Placebo (Placebo) | 餘衊願膚廠廠遞鬱糧網(獵鏇觸膚鏇餘餘範憲餘) = 願築鑰襯築廠網製壓積 鹹鬱積繭襯齋網鑰遞壓 (窪鹹獵遞範窪蓋膚繭範, 4.2) 更多 | - | 2020-12-04 | ||
(Guanfacine) | 餘衊願膚廠廠遞鬱糧網(獵鏇觸膚鏇餘餘範憲餘) = 遞夢遞壓願鏇齋鹽積餘 鹹鬱積繭襯齋網鑰遞壓 (窪鹹獵遞範窪蓋膚繭範, 2.9) 更多 | ||||||
临床2期 | 13 | placebo+guanfacine | 積壓襯構淵獵廠廠齋艱(築餘鏇憲網壓糧鑰餘觸) = 顧選蓋襯襯選鬱選製鏇 鬱網鑰簾艱獵鹹齋簾選 (壓選鹽繭鹽窪顧鹽鑰襯, 15.1) 更多 | - | 2019-08-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用